Literature DB >> 29079866

[New aspects of symptomatic MS treatment: Part 4-sexual dysfunction and eye movement disorders].

T Henze1, W Feneberg2, P Flachenecker3, D Seidel4, H Albrecht5, M Starck2, S G Meuth6.   

Abstract

The symptomatic treatment of multiple sclerosis (MS) is nowadays of similar importance as immunotherapy within a comprehensive treatment concept of this chronic disease. It makes a considerable contribution to the reduction of disabilities in activities of daily living as well as social and occupational life. Moreover, symptomatic treatment is of great importance for amelioration of the quality of life. Since our last survey of symptomatic MS treatment in 2004 and publication of the guidelines of the German Neurological Society and the Clinical Competence Network Multiple Sclerosis (Klinisches Kompetenznetz Multiple Sklerose, KKNMS) in 2014, several developments within the topics of mobility, bladder and sexual function, vision, fatigue, cognition and rehabilitation have taken place. These new findings together with further aspects of disease measurement methods and overall treatment strategies of the respective symptoms as well as treatment goals are introduced in several individual contributions. In this article the symptoms of sexual dysfunction and eye movement disorders are discussed.

Entities:  

Keywords:  Eye movement disorders; Multiple sclerosis; Review; Sexual disorders; Symptomatic therapy

Mesh:

Year:  2018        PMID: 29079866     DOI: 10.1007/s00115-017-0441-9

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  31 in total

1.  Suppression of pendular nystagmus by smoking cannabis in a patient with multiple sclerosis.

Authors:  F Schon; P E Hart; T L Hodgson; A L Pambakian; M Ruprah; E M Williamson; C Kennard
Journal:  Neurology       Date:  1999-12-10       Impact factor: 9.910

2.  Therapeutic external ophthalmoplegia with bilateral retrobulbar botulinum toxin- an effective treatment for acquired nystagmus with oscillopsia.

Authors:  G J Menon; V T Thaller
Journal:  Eye (Lond)       Date:  2002-11       Impact factor: 3.775

3.  A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis.

Authors:  J H Noseworthy; P C O'Brien; T M Petterson; J Weis; L Stevens; W K Peterson; D Sneve; S A Cross; J A Leavitt; R G Auger; B G Weinshenker; D W Dodick; D M Wingerchuk; M Rodriguez
Journal:  Neurology       Date:  2001-06-12       Impact factor: 9.910

4.  The effects of tibolone on vaginal blood flow, sexual desire and arousability in postmenopausal women.

Authors:  E Laan; R H van Lunsen; W Everaerd
Journal:  Climacteric       Date:  2001-03       Impact factor: 3.005

5.  Treatment of acquired nystagmus with botulinum A toxin.

Authors:  E M Helveston; A E Pogrebniak
Journal:  Am J Ophthalmol       Date:  1988-11-15       Impact factor: 5.258

6.  Efficacy of sildenafil in the treatment of female sexual dysfunction due to multiple sclerosis.

Authors:  Ranan Dasgupta; Oliver J Wiseman; Gorande Kanabar; Clare J Fowler; Daniel D Mikol
Journal:  J Urol       Date:  2004-03       Impact factor: 7.450

7.  The effect of pelvic floor muscle training alone or in combination with electrostimulation in the treatment of sexual dysfunction in women with multiple sclerosis.

Authors:  A C Lúcio; C A L D'Ancona; M H B M Lopes; M C Perissinotto; B P Damasceno
Journal:  Mult Scler       Date:  2014-05-29       Impact factor: 6.312

8.  Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulin.

Authors:  A Tselis; J Perumal; C Caon; S Hreha; W Ching; M Din; G Van Stavern; O Khan
Journal:  Eur J Neurol       Date:  2008-08-21       Impact factor: 6.089

Review 9.  Vision and vision-related outcome measures in multiple sclerosis.

Authors:  Laura J Balcer; David H Miller; Stephen C Reingold; Jeffrey A Cohen
Journal:  Brain       Date:  2014-11-28       Impact factor: 13.501

10.  Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial.

Authors:  Rhian Raftopoulos; Simon J Hickman; Ahmed Toosy; Basil Sharrack; Shahrukh Mallik; David Paling; Daniel R Altmann; Marios C Yiannakas; Prasad Malladi; Rose Sheridan; Ptolemaios G Sarrigiannis; Nigel Hoggard; Martin Koltzenburg; Claudia A M Gandini Wheeler-Kingshott; Klaus Schmierer; Gavin Giovannoni; David H Miller; Raju Kapoor
Journal:  Lancet Neurol       Date:  2016-01-26       Impact factor: 44.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.